Reviewer's report

Title: hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report

Version: 2 Date: 6 January 2014

Reviewer: Matteo Santoni

Reviewer's report:

Minor Essential Revisions:
In this Case report, the authors well underline the importance of a prompt management of adverse events in patients treated with targeted agents. HFS represents one of the most common toxicities associated with the use of this drugs, and this case well shows the impact that HFS may have on patient quality of life and compliance to therapy.

I suggest just to add to the conclusion two important focuses. At first, the possibility to restart this therapy at lower doses after the recovery of major toxicities. Moreover, the fact that the appearance of adverse events in the early phases of the treatment with anti-VEGFR TKIs is often associated with good response rate.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests